DE69535787D1 - Verbesserte dnase flüssige lösungen - Google Patents

Verbesserte dnase flüssige lösungen

Info

Publication number
DE69535787D1
DE69535787D1 DE69535787T DE69535787T DE69535787D1 DE 69535787 D1 DE69535787 D1 DE 69535787D1 DE 69535787 T DE69535787 T DE 69535787T DE 69535787 T DE69535787 T DE 69535787T DE 69535787 D1 DE69535787 D1 DE 69535787D1
Authority
DE
Germany
Prior art keywords
dnase
solutions
calcium ion
liquid solutions
thermal aggregation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69535787T
Other languages
English (en)
Inventor
Hak-Kim Chan
Igor Gonda
Steven J Shire
Suzanne Sin-Mui Weck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69535787D1 publication Critical patent/DE69535787D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534Mentha (mint)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9068Zingiber, e.g. garden ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • A61K38/012Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018Hydrolysed proteins; Derivatives thereof from animals from milk
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/21Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001Deoxyribonuclease I (3.1.21.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
DE69535787T 1994-03-04 1995-02-28 Verbesserte dnase flüssige lösungen Expired - Fee Related DE69535787D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20650494A 1994-03-04 1994-03-04
US37752795A 1995-01-20 1995-01-20
PCT/US1995/002457 WO1995023854A1 (en) 1994-03-04 1995-02-28 IMPROVED DNase LIQUID SOLUTIONS

Publications (1)

Publication Number Publication Date
DE69535787D1 true DE69535787D1 (de) 2008-08-28

Family

ID=26901408

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535787T Expired - Fee Related DE69535787D1 (de) 1994-03-04 1995-02-28 Verbesserte dnase flüssige lösungen

Country Status (7)

Country Link
US (2) US6383788B1 (de)
EP (1) EP0748377B1 (de)
JP (1) JP3009224B2 (de)
AT (1) ATE401394T1 (de)
CA (1) CA2184581C (de)
DE (1) DE69535787D1 (de)
WO (1) WO1995023854A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383788B1 (en) * 1994-03-04 2002-05-07 Genentech, Inc. Minimizing thermally induced aggregation of DNase in solution with calcium
CA2264885A1 (en) * 1996-09-04 1998-03-12 Nexell Therapeutics Inc. Compositions containing nucleases and chelators to enhance the recovery of cells during cell separating procedures
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CA2754528A1 (en) 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation
US20140005128A1 (en) 2010-08-11 2014-01-02 Forest Laboratories Holdings Limited Treatments of gastrointestinal disorders
EP3214172B1 (de) 2014-10-31 2019-02-13 JCR Pharmaceuticals CO., LTD. Verfahren zur herstellung rekombinanter menschlicher dnasei
US11225648B2 (en) * 2015-01-04 2022-01-18 Protalix Ltd. Modified DNase and uses thereof
WO2017049205A2 (en) * 2015-09-18 2017-03-23 Amunix Operating Inc. Growth hormone formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042587A (en) * 1960-11-29 1962-07-03 Merck & Co Inc Stabilized desoxyribonuclease preparation
CA1059937A (en) 1975-03-25 1979-08-07 Boen T. Khouw Isolation and purification of deoxyribonuclease
US4233405A (en) * 1979-10-10 1980-11-11 Rohm And Haas Company Process for spray drying enzymes
WO1990007572A1 (en) * 1988-12-23 1990-07-12 Genentech, Inc. HUMAN DNase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
US6383788B1 (en) * 1994-03-04 2002-05-07 Genentech, Inc. Minimizing thermally induced aggregation of DNase in solution with calcium
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof

Also Published As

Publication number Publication date
CA2184581C (en) 2005-02-22
US6383788B1 (en) 2002-05-07
EP0748377A1 (de) 1996-12-18
US20030054532A1 (en) 2003-03-20
JPH09503394A (ja) 1997-04-08
US7018825B2 (en) 2006-03-28
JP3009224B2 (ja) 2000-02-14
WO1995023854A1 (en) 1995-09-08
ATE401394T1 (de) 2008-08-15
CA2184581A1 (en) 1995-09-08
EP0748377B1 (de) 2008-07-16

Similar Documents

Publication Publication Date Title
SE9503143D0 (sv) New preparation
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
HUP0102033A2 (hu) PEG IFN-alfa és ribavirin felhasználása krónikus hepatitis C kezelésére
CA2059403A1 (en) Use of Carrageenans in Topical Ophthalmic Compositions
IT1246188B (it) Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
ATE234108T1 (de) Therapeutikum zur unterdrückung von schnarchgeräuschen
EP0142426A3 (de) Ophthalmische Zusammensetzung enthaltend Norfloxacin und verwandte Antibiotika
ATE401394T1 (de) Verbesserte dnase flüssige lösungen
EP0177342A3 (de) Orale Formulierungen therapeutischer Proteine
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
DK1032379T3 (da) Præparat med azelainsyre
BR9803233A (pt) Preparação de combinação farmacêutica de um inibidor do trocador de sódio/hidrogênio e um medicamento para o tratamento de doenças cardiovasculares.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
CA2189705A1 (en) Use of flupirtine for the prophylaxis and therapy of diseases associated with an impairment of the haematopoetic cell system
RU98111152A (ru) Применение активного вещества флупиртина или его фармакологически приемлемых солей в качестве лекарственного средства для профилактики и лечения заболеваний, ассоциированных с повреждением клеточной системы гемопоэза
ATE126063T1 (de) Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen.
DE69626401D1 (de) Arzneimittel zur topischen anwendung
EG17992A (en) Preparation of a medicament for arthritis and theumatism
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
RU94045140A (ru) Фармацевтическая композиция для профилактики или лечения вирусных заболеваний, способ ее получения и применение антагониста брадикинина или его физиологически переносимой соли в качестве средства для профилактики или лечения вирусных заболеваний
RU96109524A (ru) Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для иньекций
RU2000105081A (ru) Применение препарата "эсвицин" для лечения ревматоидного артрита
RU96102110A (ru) Способ профилактики и лечения изъязвлений роговицы
Bubnov et al. Familial and nonfamilial forms of arterial hypertension

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee